Anacetrapib, a cholesteryl ester transfer protein inhibitor

Bibliography

• Gordon DJ, Probstfield JL, Garrison RJ, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Klerkx AH, Stroes ES, A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74
   PubMed Web of Science ®Google Scholar
• van der Steeg WA, Hovingh GK, Klerkx AH, Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. J Lipid Res 2007;48:674-82
   PubMed Web of Science ®Google Scholar
• Nagano M, Yamashita S, Hirano K, Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 2004;11:110-21
   PubMedGoogle Scholar
• Barter PJ, Caulfield M, Eriksson M, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
   PubMed Web of Science ®Google Scholar
• Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 2009;24:364-71
   PubMed Web of Science ®Google Scholar
• Ranalletta M, Bierilo KK, Chen Y, Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010;51:2739-52
   PubMed Web of Science ®Google Scholar
• Niesor EJ, Magg C, Ogawa N, Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010;51:3443-54
   PubMed Web of Science ®Google Scholar
• Krishna R, Garg A, Panebianco D, Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009;68:535-45
   PubMed Web of Science ®Google Scholar
• Krishna R, Bergman AJ, Jin B, Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008;84:679-83
   PubMed Web of Science ®Google Scholar
• Castro-Perez J, Briand F, Gagen K, Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res 2011;52:1965-73
   PubMed Web of Science ®Google Scholar
• Tan EY, Hartmann G, Chen Q, Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos 2010;38:459-73
   PubMed Web of Science ®Google Scholar
• Kumar S, Tan EY, Hartmann G, Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos 2010;38:474-83
   PubMed Web of Science ®Google Scholar
• Krishna R, Bergman AJ, Jin B, Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol 2009;49:80-7
   PubMed Web of Science ®Google Scholar
• Garg A, Maes A, Corr C, Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects. J Clin Pharmacol 2011;51:436-9
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14
   PubMed Web of Science ®Google Scholar
• Bloomfield D, Carlson GL, Sapre A, Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-60; e2
   PubMed Web of Science ®Google Scholar
• Dansky HM, Bloomfield D, Gibbons P, Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. Am Heart J 2011;162:708-16
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Kling J, Pagler T, Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010;30:1430-8
   PubMed Web of Science ®Google Scholar
• Krishna R, Garg A, Jin B, Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2009;67:520-6
   PubMed Web of Science ®Google Scholar
• Cannon CP, Dansky HM, Davidson M, Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J 2009;158:513-19; e3
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
   PubMed Web of Science ®Google Scholar
• Krishna R, Bergman AJ, Green M, Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor. Aaps J 2011;13:179-90
   PubMed Web of Science ®Google Scholar
• Forrest MJ, Bloomfield D, Briscoe RJ, Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-73
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA, Tardif JC, Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011;124:555-62
   PubMed Web of Science ®Google Scholar
• Matsuura F, Wang N, Chen W, HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 2006;116:1435-42
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Matsuura F, Wang N, Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27:1132-8
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Vasan RS, Pencina MJ, Robins SJ, Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009;120:2414-20
   PubMed Web of Science ®Google Scholar
• Niesor EJ. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol 2011;22:288-95
   PubMed Web of Science ®Google Scholar